JP6584956B2 - 多能性幹細胞から血小板を生産するための方法およびその組成物 - Google Patents
多能性幹細胞から血小板を生産するための方法およびその組成物 Download PDFInfo
- Publication number
- JP6584956B2 JP6584956B2 JP2015549848A JP2015549848A JP6584956B2 JP 6584956 B2 JP6584956 B2 JP 6584956B2 JP 2015549848 A JP2015549848 A JP 2015549848A JP 2015549848 A JP2015549848 A JP 2015549848A JP 6584956 B2 JP6584956 B2 JP 6584956B2
- Authority
- JP
- Japan
- Prior art keywords
- platelets
- cells
- cell
- platelet
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0644—Platelets; Megakaryocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2309—Interleukin-9 (IL-9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2311—Interleukin-11 (IL-11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
- C12N2501/734—Proteases (EC 3.4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本出願は、2012年12月21日に出願された米国仮特許出願第61/740,699号および2013年3月15日に出願された米国仮特許出願第61/787,476号(両方とも「多能性幹細胞から血小板を生産するための方法およびその組成物」と題される)に対する利益を主張し、これら両方の内容全体が参照によって本明細書中に組み込まれる。
血小板は、血液凝固という重要な高度に特化した機能を果たす小さな血液細胞である。平均的なヒトの血液ではほぼ1兆個の血小板が循環し、そのターンオーバーは、全血小板集団が10日毎に置き換えられるようなものである。これは、莫大な量の進行中の血小板生成を示す。血小板は、高度に組織化された細胞骨格および300を超えるタンパク質の細胞内貯蔵を有し、血管傷害の部位においてこれらを分泌する。血小板は、炎症、血管増殖および腫瘍転移においても役割を果たす。
ヒト胚性幹細胞(hESC)は、in vitroで無制限に繁殖および拡大増殖され得、ヒト治療のための細胞の、潜在的に無尽蔵のドナーなしの供給源を提供する。in vitroでのhESCの造血細胞への分化は、過去10年間にわたって広範囲に調査されてきた。hESCの方向付けられた造血分化は、2つの異なる型の培養系によってin vitroで首尾よく達成されている。これらのうち1つは、血清含有培地中での、hESCと間質フィーダー細胞との共培養を使用する(3;4)。第2の型の手順は、血清あり/なしのサイトカインの存在下での、超低細胞結合プレートにおける懸濁培養条件を使用する(5〜7);その終点は、細胞凝集体または胚様体(「EB」)の形成である。造血先駆体ならびに赤血球、骨髄、マクロファージ、巨核球およびリンパ系の系列を示す成熟した機能的子孫が、上記分化するhESC培養系の両方において同定されている(3〜6:8〜14)。以前の研究でもまた、血清の存在下で間質細胞と共培養することによって、hESCから巨核球/血小板が生成した(15;16)。しかし、上記研究における巨核球/血小板の収量は低かった(15;16)。
本開示は、多能性幹細胞、例えば、ヒト胚性幹細胞(hESC)および人工多能性幹細胞(iPSCまたはiPS細胞)、例えばヒト人工多能性幹細胞(hiPSCまたはhiPS細胞)からの血小板の生成のための方法を提供する。これらの方法は、胚様体を形成することなく実施され得、間質インデューサー細胞の使用を伴わずに実施され得る。さらに、収量および/または純度は、多能性幹細胞から血小板を生成する以前の方法について報告されているよりも高くなり得る。血小板は、より高い効率およびより大きい規模で生成され得るので、本開示の方法および組成物は、医療上の輸血目的での使用についての大きな可能性を有する。さらに、血小板は、核を有さず、最小の遺伝子材料のみを含むので、本開示の調製物は、任意の汚染する有核細胞、例えば未分化hESCを効果的に排除するために、輸血前に照射され得る。したがって、有核細胞の起こり得る存在は、安全性の問題を示さないはずである。
であって、前記調製物が白血球を実質的に含まず、前記血小板の実質的に全てが機能的である、医薬調製物。
本開示において使用する定義および略号のリストは、詳細な説明の最後に提供する。
スチゾフィリン(stizophyllin)、マンソニン、ストレブロシド、アカゲリン(akagerine)、ジヒドロウサンバレンシン(dihydrousambaraensine)、ヒドロキシウサンバリン(hydroxyusambarine)、ストリクノペンタミン(strychnopentamine)、ストリクノフィリン(strychnophylline)、ウサンバリン(usambarine)、ウサンバレンシン(usambarensine)、ベルベリン、リリオデニン、オキソウシンスニン、ダフノレチン(daphnoretin)、ラリシレシノール、メトキシラリシレシノール、シリンガレシノール、ウンベリフェロン、アフロモソン(afromoson)、アセチルビスミオン(acetylvismione)B、デスアセチルビスミオン(desacetylvismione)A、またはビスミオン(vismione)AおよびB。
多能性由来造血性内皮細胞(PVE−HE)の生成。
ヒトiPS由来PVE−HE細胞から、剥離した巨核球系列特異的前駆体(MLP)を生成する。
ヒトiPS−PVE−HE−MLP由来巨核球(MK)からの成熟血小板の生成。
iPS−PVE−HE−MLP由来巨核球(MK)由来の成熟血小板の分析。
多能性細胞からの血小板の生成。
1)60μL/チューブの最終反応容量中に、既知の数の蛍光ビーズおよびフィコエリトリンコンジュゲート化抗CD61 IgGと共に凍結乾燥ペレットを含む1つのTruCount(BDカタログ番号340334)チューブ、ならびに
2)60μL/チューブの最終反応容量中に、非特異的一次抗体結合を説明するためにPEコンジュゲート化マウスIgGを含む1つのアイソタイプ対照チューブ。
血小板潜在力およびPAC−1結合についてのアッセイ。
剪断力下で生成された血小板の収量および純度を改善するためのMMPインヒビターなどのプロテアーゼの使用。
静置培養での血小板形成において有用な保護的インヒビターとしての、MMP8特異的インヒビター。
昇温でのiPS血小板生成。
iBETは、c−myc遺伝子の下方調節を介して、巨核球傾倒を促進し、全体的血小板収量を増加させる。
Claims (30)
- 巨核球から血小板を生成するための方法であって、
a)CD41aおよびCD42bの発現について陽性である巨核球のフィーダーフリーの非接着性培養物を提供するステップ、ここで、該巨核球は、人工多能性幹細胞(iPSC)に由来する;
b)該巨核球を、造血拡大増殖培地、TPO、SCF、IL−6およびIL−9と接触させて、培養中において前血小板の形成を引き起こすステップであって、該前血小板が血小板を放出し、および、該血小板の少なくとも60%が、CD41aおよびCD42bの発現について陽性であるステップ;および
c)該血小板を単離するステップ
を含む方法。 - 実質的に全ての前記単離された血小板が機能的である、請求項1に記載の方法。
- ステップ(b)における前記培養が、10〜100ng/mlのTPO、0.5〜100ng/mlのSCF、5〜25ng/mlのIL−6、5〜25ng/mlのIL−9、少なくとも1種のROCKインヒビター、および/または2.5〜25単位/mlのヘパリンのうち1つまたは複数を含む培地中である、請求項1または2に記載の方法。
- 前記少なくとも1種のROCKインヒビターがY27632を含む、請求項3に記載の方法。
- 前記Y27632が、2〜20μM、約3〜10μM、約4〜6μMまたは約5μMの濃度内である、請求項4に記載の方法。
- 前記巨核球を剪断力に供するステップをさらに含む、請求項1〜5のいずれか一項に記載の方法。
- 巨核球1個当たり少なくとも2個、3個、4個または5個の血小板が生成される、請求項1〜6のいずれか一項に記載の方法。
- 巨核球1個当たり少なくとも50個の血小板が生成される、請求項7に記載の方法。
- 巨核球1個当たり少なくとも100個、500個、1000個、2000個、5000個または10000個の血小板が生成される、請求項8に記載の方法。
- 前記血小板の少なくとも70%、少なくとも80%、少なくとも90%または少なくとも95%が、CD41a+およびCD42b+である、請求項1〜9のいずれか一項に記載の方法。
- 前記血小板が、フィーダー細胞または間質フィーダー細胞の非存在下で生成される、請求項1〜10のいずれか一項に記載の方法。
- 前記血小板が、全ての異種細胞の非存在下で生成される、請求項1〜11のいずれか一項に記載の方法。
- 前記血小板がヒトのものである、請求項1〜12のいずれか一項に記載の方法。
- 前記巨核球が、外因的に添加されたプロテアーゼインヒビターの存在下で培養される、請求項1〜13のいずれか一項に記載の方法。
- 前記巨核球が、外因的に添加されたMMPインヒビターの存在下で培養される、請求項1〜13のいずれか一項に記載の方法。
- 前記巨核球が、外因的に添加されたMMP8インヒビターの存在下で培養される、請求項1〜13のいずれか一項に記載の方法。
- 前記巨核球が、外因的に添加されたMMP8特異的インヒビターおよび汎MMPインヒビターの存在下で培養される、請求項1〜13のいずれか一項に記載の方法。
- 前記巨核球が、約39℃の温度で培養される、請求項1〜17のいずれか一項に記載の方法。
- 前記巨核球が、
人工多能性幹細胞を培養して、造血性内皮細胞(PVE−HE)を形成するステップ;
該造血性内皮細胞を培養して、MLPを形成するステップ;および
該MLPを培養して、巨核球を形成するステップ
を含むステップによって生成される、請求項1〜18のいずれか一項に記載の方法。 - BETインヒビターが、ステップ(b)における前記培養物に添加される、請求項19に記載の方法。
- 前記BETインヒビターがIBET151である、請求項20に記載の方法。
- 前記造血性内皮細胞が、胚様体形成なしに誘導される、請求項19〜21のいずれか一項に記載の方法。
- 前記iPSCがヒトiPSCである、請求項1に記載の方法。
- 前記造血性内皮細胞が、1%〜10%の酸素、2%〜8%の酸素、3%〜7%の酸素、4%〜6%の酸素または約5%の酸素を含む低酸素条件下で、前記人工多能性幹細胞から分化させられる、請求項19〜23のいずれか一項に記載の方法。
- 前記MLPが、38〜40セルシウス度の間の温度、または約39セルシウス度の温度で培養されて、巨核球を形成する、請求項19〜24のいずれか一項に記載の方法。
- 請求項1〜25のいずれか一項に記載の方法を使用する、血小板を含む医薬調製物を生成するための方法。
- 前記調製物が、ヒト患者における使用に適切であり、少なくとも108個の血小板を含む、請求項26に記載の方法。
- 前記調製物が、ヒト患者における使用に適切であり、白血球を実質的に含まない、請求項26に記載の方法。
- 前記調製物が、それを必要とする患者あるいは凝固に影響する疾患もしくは障害に罹患している患者またはそれによって処置可能な疾患もしくは障害に罹患している患者の処置のために使用される、請求項26〜28のいずれか一項に記載の方法。
- 前記疾患または障害が、血小板減少症、外傷、血液媒介寄生生物またはマラリアを含む、請求項29に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261740699P | 2012-12-21 | 2012-12-21 | |
US61/740,699 | 2012-12-21 | ||
US201361787476P | 2013-03-15 | 2013-03-15 | |
US61/787,476 | 2013-03-15 | ||
PCT/US2013/077334 WO2014100779A1 (en) | 2012-12-21 | 2013-12-21 | Methods ofr production of platelets from pluripotent stem cells and compositions thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019128551A Division JP6875464B2 (ja) | 2012-12-21 | 2019-07-10 | 多能性幹細胞から血小板を生産するための方法およびその組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016504339A JP2016504339A (ja) | 2016-02-12 |
JP2016504339A5 JP2016504339A5 (ja) | 2017-02-09 |
JP6584956B2 true JP6584956B2 (ja) | 2019-10-02 |
Family
ID=50979299
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015549848A Active JP6584956B2 (ja) | 2012-12-21 | 2013-12-21 | 多能性幹細胞から血小板を生産するための方法およびその組成物 |
JP2019128551A Active JP6875464B2 (ja) | 2012-12-21 | 2019-07-10 | 多能性幹細胞から血小板を生産するための方法およびその組成物 |
JP2021072813A Active JP7432554B2 (ja) | 2012-12-21 | 2021-04-22 | 多能性幹細胞から血小板を生産するための方法およびその組成物 |
JP2023204772A Pending JP2024070856A (ja) | 2012-12-21 | 2023-12-04 | 多能性幹細胞から血小板を生産するための方法およびその組成物 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019128551A Active JP6875464B2 (ja) | 2012-12-21 | 2019-07-10 | 多能性幹細胞から血小板を生産するための方法およびその組成物 |
JP2021072813A Active JP7432554B2 (ja) | 2012-12-21 | 2021-04-22 | 多能性幹細胞から血小板を生産するための方法およびその組成物 |
JP2023204772A Pending JP2024070856A (ja) | 2012-12-21 | 2023-12-04 | 多能性幹細胞から血小板を生産するための方法およびその組成物 |
Country Status (8)
Country | Link |
---|---|
US (8) | US9763984B2 (ja) |
EP (2) | EP3973967A1 (ja) |
JP (4) | JP6584956B2 (ja) |
CN (2) | CN105101979B (ja) |
CA (2) | CA3177929A1 (ja) |
ES (1) | ES2896354T3 (ja) |
HK (2) | HK1216148A1 (ja) |
WO (1) | WO2014100779A1 (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210003301A (ko) * | 2008-05-06 | 2021-01-11 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법 |
CA3177929A1 (en) | 2012-12-21 | 2014-06-26 | Astellas Institute For Regenerative Medicine | Methods for production of platelets from pluripotent stem cells and compositions thereof |
CA2925774A1 (en) | 2013-10-01 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human ipsc-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings |
US11802270B2 (en) | 2014-08-07 | 2023-10-31 | Tufts University | Microphysiologic methods and compositions |
US10725041B2 (en) * | 2014-11-04 | 2020-07-28 | Versiti Blood Research Institute Foundation, Inc. | Method to bioengineer designer platelets using gene editing and stem cell methodologies |
SG11201703544QA (en) * | 2014-11-07 | 2017-06-29 | Univ Osaka | Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same |
CA2969417A1 (en) * | 2014-12-05 | 2016-06-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
CN107429230B (zh) | 2015-01-26 | 2021-11-12 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
SE539096C2 (en) * | 2015-03-18 | 2017-04-04 | C Conjunction Ab | A method, system and software application for providing context based commercial information |
IL293110B2 (en) | 2015-03-23 | 2023-11-01 | Astellas Inst For Regenerative Medicine | Improved assays for the potential of retinal pigment epithelium (RPE) cells and photoreceptor progenitors |
WO2016160860A1 (en) * | 2015-03-30 | 2016-10-06 | Loh Jeffrey Thomas | Methods for in vitro production of platelets and compositions and uses thereof |
ES2839220T3 (es) * | 2015-06-16 | 2021-07-05 | Univ Kyoto | Procedimiento de fabricación de plaquetas de alto rendimiento |
TWI772270B (zh) | 2015-08-18 | 2022-08-01 | 美商安斯泰來再生醫藥協會 | 臨床調配物 |
US20180334652A1 (en) * | 2015-09-08 | 2018-11-22 | Brigham And Women's Hospital, Inc. | System and Method for Producing Blood Platelets |
CN108026511B (zh) | 2015-09-15 | 2021-09-24 | 株式会社美加细胞 | 利用旋转式搅拌培养法的血小板的制造方法 |
RU2766177C2 (ru) | 2015-10-14 | 2022-02-08 | Мегакарион Корпорейшн | Способ получения очищенных тромбоцитов |
DK3372674T3 (da) * | 2015-11-02 | 2020-10-12 | Megakaryon Corp | Fremgangsmåde til fremstilling af blodplader under anvendelse af røreindretning med frem- og tilbagegående rørebevægelse |
CA3003152A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
CN115806940A (zh) | 2015-11-04 | 2023-03-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
CN105553951B (zh) * | 2015-12-08 | 2019-11-08 | 腾讯科技(深圳)有限公司 | 数据传输方法和装置 |
CN105749252A (zh) * | 2016-04-29 | 2016-07-13 | 南方医科大学 | Il-9作为治疗血小板缺少症的药物的应用 |
CA2937157A1 (en) | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
ES2676535B1 (es) * | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
US20200056141A1 (en) * | 2017-04-14 | 2020-02-20 | Hitachi High-Technologies Corporation | Charged Particle Beam Apparatus and Cell Evaluation Method |
GB201707143D0 (en) | 2017-05-04 | 2017-06-21 | Plasticell Ltd | Method for producing cells |
JPWO2018207565A1 (ja) * | 2017-05-12 | 2020-02-27 | 富士フイルム株式会社 | 分離基材、細胞分離フィルターおよび血小板の製造方法 |
JP6999918B2 (ja) * | 2017-08-21 | 2022-02-04 | 学校法人慶應義塾 | 血小板表面抗原と間葉系細胞表面抗原を共発現する血小板様細胞を含む創傷治癒促進剤 |
EP3680325A4 (en) * | 2017-09-19 | 2021-06-16 | Megakaryon Corporation | PLATELET PRODUCTION PROCESS, PLATELET PREPARATION PRODUCTION PROCESS AND BLOOD PREPARATION PRODUCTION PROCESS |
US11773374B2 (en) * | 2017-09-19 | 2023-10-03 | Megakaryon Corporation | Method for producing purified platelets, method for producing platelet product, method for producing blood product, platelet preserving solution, platelet preserving agent, and method for preserving platelets |
TWI640630B (zh) * | 2017-11-21 | 2018-11-11 | 元智大學 | 不具胎牛血清之細胞冷凍保存組合物 |
EP3735457A4 (en) * | 2018-01-05 | 2021-08-25 | Platelet Biogenesis, Inc. | COMPOSITIONS AND METHOD OF MANUFACTURING MEGAKARYOCYTE |
EP3813853A4 (en) * | 2018-06-29 | 2022-04-06 | Platelet Biogenesis, Inc. | DELIVERY COMPOSITIONS AND METHODS OF USE |
US20200208110A1 (en) * | 2018-11-30 | 2020-07-02 | Cellphire, Inc. | PLATELETS LOADED WITH mRNA |
WO2020185856A1 (en) * | 2019-03-11 | 2020-09-17 | The Children's Medical Center Corporation | Methods for increasing platelet production |
CA3135852A1 (en) * | 2019-04-03 | 2020-10-08 | Akron Biotechnology, Llc | Cryopreservation and cell culture media |
AU2020267368B2 (en) | 2019-05-03 | 2023-05-04 | Cellphire, Inc. | Materials and methods for producing blood products |
CN115003794A (zh) | 2019-08-28 | 2022-09-02 | 安斯泰来再生医药协会 | 治疗血管疾病的组合物和方法 |
TW202122577A (zh) * | 2019-08-28 | 2021-06-16 | 安斯泰來再生醫藥協會 | 治療血管疾病之方法 |
US20210214692A1 (en) * | 2019-11-20 | 2021-07-15 | City Of Hope | Methods of reprogramming somatic cells and materials related thereto |
WO2021158645A1 (en) | 2020-02-04 | 2021-08-12 | Cellphire, Inc. | Methods of treating congenital hemophilia with anti-fibrinolytic loaded platelets |
CN111249291B (zh) * | 2020-03-19 | 2023-07-18 | 广西馨海药业科技有限公司 | 白头翁皂苷b4在制备治疗/预防细菌性肺炎药物的用途 |
US20230212516A1 (en) * | 2020-06-02 | 2023-07-06 | Cornell University | Methods for expanding hematopoietic stem cells |
WO2021257802A1 (en) * | 2020-06-19 | 2021-12-23 | The Children's Medical Center Corporation | Compositions and methods for red blood cell differentiation |
GB202014727D0 (en) * | 2020-09-18 | 2020-11-04 | Univ Bristol | Platelet generation |
US20230372330A1 (en) * | 2020-10-13 | 2023-11-23 | New York Blood Center, Inc. | Compounds for treatment of hemolysis-and inflammasome-associated diseases |
CN114736284B (zh) * | 2022-04-22 | 2022-12-16 | 广州蕊特生物科技有限公司 | 一种从尿液中提取β2-微球蛋白的方法 |
CN115372233B (zh) * | 2022-10-25 | 2023-03-24 | 华夏源(上海)生命科技有限公司 | 一种脂肪干细胞细胞周期的检测方法 |
CN115772496A (zh) * | 2023-02-10 | 2023-03-10 | 山东兴瑞生物科技有限公司 | 一种诱导性多能干细胞制备通用血小板的方法 |
CN116410924A (zh) * | 2023-06-08 | 2023-07-11 | 广州正源生物技术有限公司 | 一种体外生产血小板的方法 |
Family Cites Families (221)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US911717A (en) | 1908-10-12 | 1909-02-09 | Allen W D Mfg Co | Sprinkler-head. |
US4877805A (en) | 1985-07-26 | 1989-10-31 | Kligman Albert M | Methods for treatment of sundamaged human skin with retinoids |
US4923807A (en) | 1984-05-18 | 1990-05-08 | New England Medical Center Hospitals Inc. | Arg-Serpin human plasminogen activator inhibitor designated PAI-2 |
US4911717A (en) | 1987-06-18 | 1990-03-27 | Gaskill Iii Harold V | Intravasular artificial organ |
US5128259A (en) | 1989-10-27 | 1992-07-07 | Hahnemann University | Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation |
US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
CA2109085C (en) | 1991-04-25 | 2003-03-11 | Keith E. Dionne | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
US5403272A (en) | 1992-05-29 | 1995-04-04 | Baxter International Inc. | Apparatus and methods for generating leukocyte free platelet concentrate |
EP0655910A4 (en) | 1992-07-29 | 1996-02-28 | Univ Washington | USE OF A POCKET FOR THE IMPLANTATION OF LIVING CELLS. |
US5599705A (en) | 1993-11-16 | 1997-02-04 | Cameron; Robert B. | In vitro method for producing differentiated universally compatible mature human blood cells |
ATE213771T1 (de) | 1993-12-23 | 2002-03-15 | Infigen Inc | Embryonale stammzellen von huftieren als kerndonatoren und kerntransfertechniken zur herstellung chimärer und transgener tiere |
SG47030A1 (en) * | 1994-01-03 | 1998-03-20 | Genentech Inc | Thrombopoietin |
GB9405076D0 (en) | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
US5914268A (en) | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
US5874301A (en) | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
US6485723B1 (en) | 1995-02-10 | 2002-11-26 | Purdue Research Foundation | Enhanced submucosal tissue graft constructs |
IL123832A0 (en) * | 1995-10-05 | 1998-10-30 | Searle & Co | Multi-functional hematopoietic receptor antagonists |
US5855613A (en) | 1995-10-13 | 1999-01-05 | Islet Sheet Medical, Inc. | Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change |
US5837224A (en) | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
ZA9711121B (en) | 1996-12-13 | 1998-06-23 | Handelman Joseph H | Reduction of hair growth. |
US6194207B1 (en) | 1997-01-31 | 2001-02-27 | Hemosol Inc. | Methods for the selective expansion of lymphocytes by in vitro cultivation |
CN100360121C (zh) | 1997-02-25 | 2008-01-09 | 密执安州立大学董事会 | 防护和处理人皮肤经时性衰老的方法和组合物 |
US6794358B1 (en) | 1997-03-28 | 2004-09-21 | Brigham And Women's Hospital | Peptide ligands of the urokinase receptor |
EP0983345A1 (en) | 1997-05-21 | 2000-03-08 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells |
TWI234467B (en) | 1997-06-04 | 2005-06-21 | Univ Michigan | Composition for inhibiting photoaging of skin |
US20050058709A1 (en) | 1997-06-04 | 2005-03-17 | Fisher Gary J. | Methods for inhibiting photoaging of human skin using orally-administered agent |
US6429012B1 (en) | 1997-10-06 | 2002-08-06 | Viacell, Inc. | Cell population containing non-fetal hemangioblasts and method for producing same |
US20010039287A1 (en) | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US6750228B1 (en) | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
NZ503485A (en) | 1997-11-14 | 2002-10-25 | G | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US20010014688A1 (en) | 1997-11-14 | 2001-08-16 | Thomas E. Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
PT1041974E (pt) | 1997-12-30 | 2007-01-31 | Alza Corp | Sistema de entrega de agente benéfico como obturador de membrana |
US20020049237A1 (en) | 1998-03-17 | 2002-04-25 | Newton Roger Schofield | Statin-MMP inhibitor combinations |
US6683069B1 (en) | 1998-04-02 | 2004-01-27 | Regents Of The University Of Michigan | Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin |
FR2778558B1 (fr) | 1998-05-12 | 2001-02-16 | Oreal | Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute |
US6361998B1 (en) | 1998-06-25 | 2002-03-26 | Hemosol Inc. | Efficient culture of stem cells for the production of hemoglobin |
JP2002523039A (ja) | 1998-08-24 | 2002-07-30 | ティー.ブリーダーズ,インコーポレイテッド | 非胎児血管芽細胞を含む細胞集団、およびその生産方法 |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
HU229520B1 (en) * | 1999-02-12 | 2014-01-28 | Scripps Research Inst | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
GB9907908D0 (en) | 1999-04-07 | 1999-06-02 | Bataille Regis | Organic compounds |
FR2792202B1 (fr) | 1999-04-19 | 2003-06-13 | Pharmascience Lab | Extrait peptidique de lupin et composition pharmaceutique ou cosmetique ou nutraceutique comprenant un tel extrait |
US20050020607A1 (en) | 1999-05-03 | 2005-01-27 | Newton Roger Schofield | Statin-MMP inhibitor combinations |
BR0014864A (pt) | 1999-10-15 | 2002-11-19 | Advanced Cell Tech Inc | Métodos de produzir células progenitoras diferenciadas e células tronco embriÈnicas defeituosas em linhagem |
WO2001032658A1 (fr) | 1999-11-02 | 2001-05-10 | Ajinomoto Co., Inc. | Compose de polyazanaphtalene et utilisation medicinale dudit compose |
JP2003530826A (ja) | 1999-11-17 | 2003-10-21 | ユニバーシティー オブ ロチェスター | ヒトのエキソビボ免疫系 |
US6699486B1 (en) | 1999-11-18 | 2004-03-02 | Bolla Corporation | Treatment or prevention of photoaging and skin cancer |
WO2001050848A2 (en) | 2000-01-07 | 2001-07-19 | Oregon Health And Science University | Clonal propagation of primate offspring by embryo splitting |
US7455983B2 (en) * | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
US7795026B2 (en) | 2000-01-21 | 2010-09-14 | The Johns Hopkins University School Of Medicine | Methods for obtaining human embryoid body-derived cells |
US6602711B1 (en) | 2000-02-21 | 2003-08-05 | Wisconsin Alumni Research Foundation | Method of making embryoid bodies from primate embryonic stem cells |
US20020010162A1 (en) | 2000-03-02 | 2002-01-24 | Raul Fleischmajer | Treatment of psoriasis with matrix metalloproteinase inhibitors |
CA2372352A1 (en) | 2000-04-07 | 2001-10-18 | Hyun-Gyu Park | Sulfonamide derivative as a matrix metalloproteinase inhibitor |
AU7311501A (en) | 2000-06-29 | 2002-03-22 | Quick Med Technologies Inc | Cosmetic composition and method |
US20040185127A1 (en) | 2001-06-29 | 2004-09-23 | Lerner David S. | Cosmetic composition and method |
EP1174129A1 (en) | 2000-07-17 | 2002-01-23 | Zenner, Hans Peter, Prof. Dr. med. | Use of a matrix-metalloprotease inhibitor for the treatment of cancer |
JP2004504834A (ja) | 2000-08-01 | 2004-02-19 | イスム リサーチ ディベロップメント カンパニー | 胚性細胞の定方向分化 |
EP1352060A2 (en) * | 2000-10-30 | 2003-10-15 | Novozymes Biotech, Inc. | Methods for expressing endogenous genes by restriction enzyme mediated integration |
DE60235967D1 (de) | 2001-01-29 | 2010-05-27 | Ivan N Rich | ATP-basierter Assay zur Bestimmung der Proliferation hämatopoetischer Stamm- und Vorläuferzellen |
US6511473B2 (en) | 2001-01-30 | 2003-01-28 | Biodepo, Inc. | Implantable bioartificial active secretion system |
GB0103303D0 (en) | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
US20030027330A1 (en) | 2001-04-02 | 2003-02-06 | Robert Lanza | Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells |
KR20020083634A (ko) | 2001-04-27 | 2002-11-04 | 크레아젠 주식회사 | 수지상 세포를 포함하는 자가면역 질환의 치료용 약제학적조성물 및 이를 이용한 치료방법 |
US6861504B2 (en) * | 2001-05-03 | 2005-03-01 | Cbr, Inc. | Compounds and methods for the modulation of CD154 |
CA2447015A1 (en) | 2001-05-15 | 2002-11-21 | Rappaport Family Institute For Research In The Medical Sciences | Insulin producing cells derived from human embryonic stem cells |
FR2826266B1 (fr) | 2001-06-26 | 2005-02-25 | Oreal | Composition cosmetique ou dermatologique comprenant une association entre un compose de la famille des n-acylaminoamides et au moins un inhibiteur de metalloproteinases matricielles |
EP1424389A4 (en) * | 2001-08-07 | 2004-08-25 | Kirin Brewery | PROCESS FOR THE PREPARATION OF MULTIPOTENT HEMATOPOIETIC STEM CELLS |
US6906036B2 (en) | 2001-08-16 | 2005-06-14 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
WO2003038072A1 (en) | 2001-10-31 | 2003-05-08 | Universite Libre De Bruxelles | Generation and use of new types of dendritic cells |
NZ532170A (en) | 2001-11-02 | 2008-05-30 | Wisconsin Alumni Res Found | Endothelial cells derived from primate embryonic stem cells |
US7176217B2 (en) | 2001-11-13 | 2007-02-13 | Shiseido Co., Ltd. | Azabicyclo compound matrix metalloprotease inhibitor and skin preparation |
EP1456374A4 (en) | 2001-11-26 | 2005-08-17 | Advanced Cell Tech Inc | METHODS FOR THE PRODUCTION AND USE OF REPROGRAMME HUMAN SOMATIC CELL CORES AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS |
KR20130072272A (ko) | 2001-12-07 | 2013-07-01 | 제론 코포레이션 | 인간 배아 줄기세포 유래의 조혈세포 |
AU2002359951B8 (en) * | 2001-12-28 | 2008-11-06 | Asubio Pharma Co., Ltd. | Promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors |
TWI280128B (en) | 2002-05-22 | 2007-05-01 | Smithkline Beecham Corp | 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
US20040006077A1 (en) | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
AU2003269801A1 (en) | 2002-06-28 | 2004-01-19 | Bristol Myers Squibb Company | Asymmetric synthesis of amino-pyrrolidinones and a crystalline, free-base amino-pyrrolidinone |
US20060165666A1 (en) | 2002-07-12 | 2006-07-27 | Lim Sai K | Hemangioblast progenitor cells |
US20040052771A1 (en) | 2002-07-12 | 2004-03-18 | Lim Sai Kiang | Hemangioblast progenitor cells |
AU2003247024A1 (en) | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
AU2003281167A1 (en) | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
JP2006502114A (ja) | 2002-07-17 | 2006-01-19 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリクスメタロプロテイナーゼ−13のアロステリックアルキン阻害薬とセレコキシブまたはバルデコキシブとの組合せ |
JP2006503811A (ja) | 2002-07-17 | 2006-02-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | アロステリックカルボキシルマトリックスメタロプロテイナーゼ−13阻害薬とセレコキシブまたはバルデコキシブとの組み合わせ |
BR0312666A (pt) | 2002-07-17 | 2005-05-10 | Warner Lambert Co | Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com um inibidor seletivo da cicloxigenase-2 à exceção de celecoxib e do valdecoxib |
JP2006503812A (ja) | 2002-07-17 | 2006-02-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | アロステリックカルボキシルマトリックスメタロプロテイナーゼ−13阻害薬とセレコキシブまたはバルデコキシブではない選択的シクロオキシゲナーゼ−2阻害薬との組み合わせ |
CA2496319A1 (en) | 2002-09-13 | 2004-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian megakaryocyte progenitor cell |
US7427603B2 (en) | 2002-09-26 | 2008-09-23 | The Children's Medical Center Corporation | Method of enhancing proliferation and/or hematopoietic differentiation of stem cells |
AU2002348947A1 (en) | 2002-09-26 | 2004-04-19 | Institut National De La Sante Et De La Recherche Medicale | Compositions and methods for amplification of human stem cells |
WO2004044146A2 (en) | 2002-11-06 | 2004-05-27 | Piniella Carlos J | Pluripotent cells from monocytes, and methods of making and using pluripotent cells |
US20040136973A1 (en) | 2002-11-07 | 2004-07-15 | Eliezer Huberman | Human stem cell materials and methods |
US20050032210A1 (en) | 2003-03-18 | 2005-02-10 | Kirin Beer Kabushiki Kaisha | Method of preparing immuno-regulatory dendritic cells and the use thereof |
US7579433B2 (en) | 2003-04-30 | 2009-08-25 | National University Of Singapore | Methods and compositions for treatment of arthritis and cancer |
US20040229350A1 (en) | 2003-05-12 | 2004-11-18 | Nikolai Strelchenko | Morula derived embryonic stem cells |
WO2005002585A1 (en) | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
US7476326B2 (en) | 2003-09-26 | 2009-01-13 | Ahn Chong H | On-chip sample preparation for whole blood analysis |
WO2005040391A1 (en) | 2003-10-27 | 2005-05-06 | Murdoch Childrens Research Institute | Compositions and methods for differentiating stem cells |
WO2005049812A1 (en) | 2003-11-19 | 2005-06-02 | Australian Stem Cell Centre Limited | Methods for producing blood products from pluripotent cells in cell culture |
CN1286970C (zh) * | 2003-12-30 | 2006-11-29 | 上海伯瑞生物技术发展有限公司 | 由脐血cd34+细胞体外诱导生成巨核细胞的方法 |
KR100535326B1 (ko) | 2004-01-20 | 2005-12-09 | 한국생명공학연구원 | 줄기 세포로부터 자연살해 세포로의 분화 조절용 유전자를유효성분으로 포함하는 분화 조절제 |
KR20060114366A (ko) | 2004-02-09 | 2006-11-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 | 클론원성 내피 전구 세포의 분리, 팽창 및 용도 |
US20050221482A1 (en) | 2004-03-31 | 2005-10-06 | Burt Richard K | Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof |
KR100479678B1 (ko) | 2004-04-20 | 2005-03-31 | 원종칠 | 양변기의 가변 사이폰관 구동장치 |
EP1755586A2 (en) | 2004-04-29 | 2007-02-28 | The Regents of the University of California | Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
WO2005110399A2 (en) | 2004-04-29 | 2005-11-24 | The Regents Of The University Of California | Zinc-binding groups for metalloprotein inhibitors |
JP2007536935A (ja) | 2004-05-14 | 2007-12-20 | ベクトン・ディキンソン・アンド・カンパニー | 間葉幹細胞の無血清増殖のための細胞培養環境 |
WO2006001954A2 (en) | 2004-05-20 | 2006-01-05 | Puget Sound Blood Center And Program | Methods for promoting the formation of platelets and for treating blood and bone marrow disorders |
US8206979B2 (en) | 2004-06-04 | 2012-06-26 | Universite Pierre et Marie Curie — Paris VI | Method for producing red blood cells |
CN101006172B (zh) | 2004-06-24 | 2012-09-05 | 株式会社载体研究所 | 包含导入了rna病毒的树突状细胞的抗癌剂 |
EP2626415A3 (en) | 2004-10-25 | 2014-04-16 | Cellerant Therapeutics, Inc. | Methods of expanding myeloid cell populations and uses thereof |
CN101052710A (zh) * | 2004-11-01 | 2007-10-10 | 威斯康星校友研究基金会 | 来自干细胞的血小板 |
US20070077654A1 (en) | 2004-11-01 | 2007-04-05 | Thomson James A | Platelets from stem cells |
MX2007005200A (es) * | 2004-11-01 | 2007-05-11 | Wisconsin Alumni Res Found | Plaquetas a partir de celulas germinales. |
US7893315B2 (en) | 2004-11-04 | 2011-02-22 | Advanced Cell Technology, Inc. | Derivation of embryonic stem cells and embryo-derived cells |
US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
US20080166751A1 (en) | 2005-02-23 | 2008-07-10 | Takayuki Asahara | Method of Analyzing Dynamics in the Differentiation of Vascular Endothelial Progenitor Cells |
JP4964121B2 (ja) | 2005-02-23 | 2012-06-27 | 財団法人先端医療振興財団 | 血管内皮前駆細胞の生体外増幅方法 |
EP2399594B1 (en) | 2005-03-17 | 2019-08-14 | UCL Business PLC | Tumour cell-activated Natural Killer cells |
CN101310007A (zh) * | 2005-04-19 | 2008-11-19 | 约翰·霍普金斯大学 | 使用来自脐带血的基质细胞将来自脐带血的有核细胞增量(expanding)及移植(engrafting)的方法 |
EP1910367A2 (en) | 2005-05-20 | 2008-04-16 | Alantos Pharmaceuticals, Inc. | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
WO2006130651A2 (en) | 2005-06-01 | 2006-12-07 | Wisconsin Alumni Research Foundation | Method of forming dendritic cells from embryonic stem cells |
WO2007005595A1 (en) | 2005-07-05 | 2007-01-11 | The New England Medical Center Hospitals, Inc. | Pregnancy-associated progenitor cells |
US9121008B2 (en) | 2005-08-31 | 2015-09-01 | University Of Utah Research Foundation | Development of natural killer cells and functional natural killer cell lines |
WO2007032634A1 (en) | 2005-09-12 | 2007-03-22 | Industry Foundation Of Chonnam National University | A method for production of mature natural killer cell |
JP2007089432A (ja) | 2005-09-27 | 2007-04-12 | Reprocell Inc | 幹細胞由来血小板産生増加法 |
PL1941027T3 (pl) | 2005-09-28 | 2015-01-30 | Ipd Therapeutics B V | Metody i środki do proliferacji komórek macierzystych oraz wytwarzania i ekspansji komórek progenitorowych, a także produkcji komórek efektorowych jako leków klinicznych |
CN100336907C (zh) * | 2005-09-29 | 2007-09-12 | 南京大学 | 重组人血小板生成素/干细胞因子融合蛋白及其制备 |
WO2007095064A2 (en) | 2006-02-09 | 2007-08-23 | Wisconsin Alumni Research Foundation | ERYTHROID CELLS PRODUCING ADULT-TYPE β-HEMOGLOBIN GENERATED FROM HUMAN EMBRYONIC STEM CELLS |
CN101045914A (zh) | 2006-03-29 | 2007-10-03 | 中国人民解放军军事医学科学院野战输血研究所 | 体外诱导造血干/祖细胞分化为成熟红细胞的方法与应用 |
CN101045915A (zh) | 2006-03-29 | 2007-10-03 | 旭日干 | 一种卵母细胞生发泡移植技术 |
KR20230145494A (ko) | 2006-04-14 | 2023-10-17 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | 혈관 콜로니 형성 세포 |
US20070243608A1 (en) * | 2006-04-14 | 2007-10-18 | Board Of Regents, The University Of Texas System | Platelet bioreactor |
AU2013201444B2 (en) | 2006-04-14 | 2015-01-22 | Astellas Institute For Regenerative Medicine | Hemangio-colony forming cells |
NZ572842A (en) | 2006-04-14 | 2012-01-12 | Advanced Cell Tech Inc | Hemangio-colony forming cells |
JP2009539378A (ja) * | 2006-06-09 | 2009-11-19 | アントフロゲネシス コーポレーション | 胎盤環境及び幹細胞を培養するためのその使用 |
CN101500609A (zh) * | 2006-06-14 | 2009-08-05 | 中外制药株式会社 | 造血干细胞增加促进剂 |
US20070298496A1 (en) | 2006-06-23 | 2007-12-27 | Hung-Chih Kuo | Method of deriving pluripotent stem cells from a single blastomere |
WO2008024784A1 (en) | 2006-08-22 | 2008-02-28 | Array Biopharma, Inc. | Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors |
US7718420B2 (en) | 2006-10-10 | 2010-05-18 | Postech Academy-Industry Foundation | Microfluidic biochip for blood typing based on agglutination reaction |
WO2008067142A2 (en) | 2006-11-08 | 2008-06-05 | Wisconsin Alumni Research Foundation | In vitro differentiation of hematopoietic cells from primate embryonic stem cells |
JP5067949B2 (ja) | 2006-11-09 | 2012-11-07 | 独立行政法人国立国際医療研究センター | 霊長類動物胚性幹細胞の培養及び継代方法、並びにその分化誘導方法 |
EP2120998B1 (en) * | 2006-11-28 | 2013-08-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Brd2ブロモドメイン結合剤 |
JP5646990B2 (ja) | 2007-04-23 | 2014-12-24 | ストワーズ インスティテュート フォー メディカル リサーチ | 幹細胞自己複製のための方法及び組成物 |
CN101063110B (zh) * | 2007-04-26 | 2011-07-20 | 上海交通大学 | 成体干细胞的培养基和培养方法 |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
WO2008151386A1 (en) | 2007-06-15 | 2008-12-18 | Australian Stem Cell Centre Ltd | Megakaryocyte differentiation |
WO2008151390A1 (en) | 2007-06-15 | 2008-12-18 | Australian Stem Cell Centre Ltd | Differentiation of human embryonic stem cells |
EP2188369A4 (en) | 2007-09-04 | 2011-12-07 | Univ Queensland | FEEDER CELL-FREE CULTURE MEDIUM AND SYSTEM |
WO2009045360A2 (en) | 2007-09-28 | 2009-04-09 | Celgene Cellular Therapeutics | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
AU2008312007A1 (en) * | 2007-10-12 | 2009-04-23 | Advanced Cell Technology, Inc. | Improved methods of producing RPE cells and compositions of RPE cells |
US20100304480A1 (en) | 2007-10-19 | 2010-12-02 | Goodell Margaret A | Hematopoietic Fingerprints: Methods of Use |
US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
US8835104B2 (en) | 2007-12-20 | 2014-09-16 | Fenwal, Inc. | Medium and methods for the storage of platelets |
WO2009084693A1 (ja) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
CA2714535A1 (en) | 2008-02-11 | 2009-08-20 | Duke University | Aptamer inhibitors of osteopontin and methods of use thereof |
WO2009104825A1 (en) | 2008-02-18 | 2009-08-27 | Kaist | Method for inducing the defferentiation of embryonic stem cells into hemangioblast |
JPWO2009119105A1 (ja) * | 2008-03-28 | 2011-07-21 | 国立大学法人 東京大学 | GPIbα+GPV+GPVI+血小板のインビトロ調製法 |
JP5617631B2 (ja) | 2008-04-01 | 2014-11-05 | 国立大学法人東京大学 | iPS細胞からの血小板の調製方法 |
KR20210003301A (ko) | 2008-05-06 | 2021-01-11 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법 |
CA2722693C (en) | 2008-05-06 | 2023-03-21 | Advanced Cell Technology, Inc. | Hemangio colony forming cells and non-engrafting hemangio cells |
JP5419076B2 (ja) | 2008-05-15 | 2014-02-19 | 旭化成メディカル株式会社 | 血小板の誘導方法 |
US20110280861A1 (en) | 2008-08-08 | 2011-11-17 | Massachusetts Institute Of Technology | Method for mir-125a in promoting hematopoietic stem cell self renewal and expansion |
JP5639058B2 (ja) | 2008-09-03 | 2014-12-10 | メソブラスト,インコーポレーテッド | 造血前駆細胞の増殖 |
US8933071B2 (en) | 2008-11-07 | 2015-01-13 | Northwestern University | Dimethyl fasudil for inducing polyploidization of megakaryocytes and for treating blood and bone marrow diseases and disorders |
HUE027112T2 (en) | 2008-12-04 | 2016-08-29 | Inserm (Institut Nat De La Sante Et De La Rech Medicale) | Procedure for producing platelets |
WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
WO2010085555A1 (en) * | 2009-01-21 | 2010-07-29 | The General Hospital Corporation | Methods for expansion of hematopoietic stem and progenitor cells |
CN101530427B (zh) * | 2009-02-03 | 2011-05-04 | 重庆西南医院 | 促造血的药物组合物及其制备方法 |
WO2010096746A1 (en) | 2009-02-20 | 2010-08-26 | Cellular Dynamics International, Inc. | Methods and compositions for the differentiation of stem cells |
US8372642B2 (en) | 2009-02-27 | 2013-02-12 | Cellular Dynamics International, Inc. | Differentiation of pluripotent cells |
US20100248361A1 (en) | 2009-03-24 | 2010-09-30 | The Ohio State University Research Foundation | Platelet production methods |
WO2011006205A1 (en) | 2009-07-15 | 2011-01-20 | Regenertech Pty Limited | Method of producing progenitor cells from differentiated cells |
WO2011034073A1 (ja) | 2009-09-15 | 2011-03-24 | 国立大学法人東京大学 | 分化細胞の新規製造法 |
CN101649305B (zh) * | 2009-09-17 | 2013-10-16 | 中国医学科学院血液学研究所 | 一种从人脐带血cd34+细胞扩增巨核祖细胞的方法 |
WO2011054851A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Novel process |
JP6013187B2 (ja) | 2009-12-04 | 2016-10-25 | ステム セル アンド リジェネレイティブ メディスン インターナショナル, インコーポレイテッド | ヒト胚性幹細胞由来血管芽細胞からナチュラルキラー細胞および樹状細胞を生成する方法 |
CA3115233A1 (en) | 2009-12-04 | 2011-06-09 | Astellas Institute For Regenerative Medicine | Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions |
US8862173B2 (en) | 2009-12-10 | 2014-10-14 | Motorola Solutions, Inc. | Method for selecting media for delivery to users at an incident |
JP5777115B2 (ja) * | 2010-03-18 | 2015-09-09 | 国立大学法人京都大学 | 多能性幹細胞から中胚葉細胞への分化誘導法 |
EP2569434B1 (en) | 2010-05-14 | 2019-09-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia and related disorders |
HUE031073T2 (en) | 2010-05-14 | 2017-06-28 | Dana Farber Cancer Inst Inc | Thieno triazolo-diazepine compounds for the treatment of neoplasia |
US8785192B2 (en) * | 2010-07-07 | 2014-07-22 | Cellular Dynamics International, Inc. | Endothelial cell production by programming |
JP5876828B2 (ja) * | 2010-09-17 | 2016-03-02 | 国立大学法人 東京大学 | 血小板の機能を維持するための組成物 |
WO2012061146A1 (en) | 2010-10-25 | 2012-05-10 | The Children's Hospital Of Philadelphia | Compositions and methods for the generation of platelets and methods of use thereof |
CN102068686A (zh) * | 2011-01-21 | 2011-05-25 | 广州市恺泰生物科技有限公司 | 一种白细胞介素-12的新用途 |
JP6005666B2 (ja) | 2011-02-08 | 2016-10-12 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | プログラミングによる造血前駆細胞の生産 |
US20140045265A1 (en) * | 2011-02-16 | 2014-02-13 | Salk Institute For Biological Studies | Robust and efficient differentiation of human pluripotent stem cells to multipotent vascular progenitors |
US9803164B2 (en) | 2011-03-18 | 2017-10-31 | New York Blood Center, Inc. | Megakaryocyte and platelet production from stem cells |
CA2828015C (en) * | 2011-03-18 | 2020-06-16 | New York Blood Center, Inc. | Megakaryocyte and platelet production from stem cells |
WO2012135621A2 (en) | 2011-03-30 | 2012-10-04 | Cellular Dynamics International. Inc | Priming of pluripotent stem cells for neural differentiation |
ES2659262T3 (es) * | 2011-05-13 | 2018-03-14 | The University Of Tokyo | Célula megacariocítica polinucleada y método para la elaboración de plaquetas |
US20160145573A1 (en) | 2012-10-05 | 2016-05-26 | Velico Medical, Inc. | Platelet Protection Solution Having a Beta-Galactosidase Inhibitor |
US20140205582A1 (en) | 2011-07-06 | 2014-07-24 | Cellerant Therapeutics, Inc. | Megakaryocyte progenitor cells for production of platelets |
US9599613B2 (en) | 2011-07-20 | 2017-03-21 | University Of Washington Through Its Center For Commercialization | Photonic blood typing |
CN202190065U (zh) | 2011-08-04 | 2012-04-11 | 深圳市雄韬电源科技股份有限公司 | 一种电池保护电路 |
KR102031386B1 (ko) | 2011-10-03 | 2019-10-11 | 닛산 가가쿠 가부시키가이샤 | 다능성 간세포로부터의 거핵구 및/또는 혈소판의 제조 방법 |
CN105688214A (zh) | 2011-10-26 | 2016-06-22 | 艾米丽·A·斯坦 | 用于影响神经功能的药剂、方法和设备 |
CN108478599B (zh) | 2011-11-30 | 2022-08-02 | 安斯泰来再生医药协会 | 间充质基质细胞及其相关用途 |
WO2013158819A2 (en) | 2012-04-20 | 2013-10-24 | St. Jude Children's Research Hospital | Method for generation of conditionally immortalized hematopoietic progenitor cell lines with multiple lineage potential |
GB201210857D0 (en) | 2012-06-19 | 2012-08-01 | Cambridge Entpr Ltd | Transcription factor mediated programming towards megakaryocytes |
US9074186B2 (en) | 2012-08-15 | 2015-07-07 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
WO2014080290A2 (en) * | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
CA3177929A1 (en) | 2012-12-21 | 2014-06-26 | Astellas Institute For Regenerative Medicine | Methods for production of platelets from pluripotent stem cells and compositions thereof |
CN105051184B (zh) | 2013-01-15 | 2018-08-10 | 康奈尔大学 | 通过给定的因子将人内皮细胞重编程为造血多系祖细胞 |
WO2014123242A1 (ja) | 2013-02-08 | 2014-08-14 | 国立大学法人京都大学 | 巨核球及び血小板の製造方法 |
WO2014138485A1 (en) | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
AU2014275836A1 (en) | 2013-06-07 | 2015-12-24 | Kaken Pharmaceutical Co., Ltd. | Composition for maintaining platelet function |
US10113147B2 (en) | 2013-06-28 | 2018-10-30 | Adiposeeds, Inc. | Method for producing megakaryocytes, platelets and/or thrombopoietin using mesenchymal cells |
WO2015031347A2 (en) | 2013-08-27 | 2015-03-05 | Mayo Foundation For Medical Education And Research | Cross-linked platelet material |
US20160235889A1 (en) | 2013-09-27 | 2016-08-18 | Tufts University | Silk/platelet composition and use thereof |
CN105980057B (zh) | 2013-11-19 | 2019-08-16 | 普拉托德公司 | 生产血小板的射流装置 |
JP6580329B2 (ja) | 2014-03-31 | 2019-09-25 | シスメックス株式会社 | 未分化細胞から分化細胞および/または分化細胞の産生物を取得する方法 |
WO2015179301A1 (en) | 2014-05-19 | 2015-11-26 | Eleftherios Papoutsakis | Megakaryocytic particles and microparticles for cell therapy & fate modification of stem and progenitor cells |
EP3154338B1 (en) | 2014-06-10 | 2020-01-29 | Biomatrica, INC. | Stabilization of thrombocytes at ambient temperatures |
JP6459257B2 (ja) | 2014-07-08 | 2019-01-30 | 富士ゼロックス株式会社 | 画像形成装置 |
US10725041B2 (en) | 2014-11-04 | 2020-07-28 | Versiti Blood Research Institute Foundation, Inc. | Method to bioengineer designer platelets using gene editing and stem cell methodologies |
JP6774952B2 (ja) * | 2015-01-16 | 2020-10-28 | エージェンシー フォー サイエンス, テクノロジー アンド リサーチ | 多能性幹細胞のマクロファージへの分化 |
CN107429230B (zh) * | 2015-01-26 | 2021-11-12 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
WO2016160860A1 (en) | 2015-03-30 | 2016-10-06 | Loh Jeffrey Thomas | Methods for in vitro production of platelets and compositions and uses thereof |
CA3038701A1 (en) * | 2016-10-05 | 2018-04-12 | FUJIFILM Cellular Dynamics, Inc. | Methods for directed differentiation of pluripotent stem cells to hla homozygous immune cells |
AU2018358241A1 (en) * | 2017-10-31 | 2020-05-07 | Edigene Biotechnology, Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
AU2020219736A1 (en) * | 2019-02-04 | 2021-09-30 | Xenetic Biosciences, Inc. | Methods of using glycopolysialylated therapeutic proteins |
-
2013
- 2013-12-21 CA CA3177929A patent/CA3177929A1/en active Pending
- 2013-12-21 WO PCT/US2013/077334 patent/WO2014100779A1/en active Application Filing
- 2013-12-21 JP JP2015549848A patent/JP6584956B2/ja active Active
- 2013-12-21 CN CN201380073429.7A patent/CN105101979B/zh active Active
- 2013-12-21 US US14/138,008 patent/US9763984B2/en active Active
- 2013-12-21 EP EP21196318.6A patent/EP3973967A1/en active Pending
- 2013-12-21 EP EP13865661.6A patent/EP2934555B1/en active Active
- 2013-12-21 CN CN202111083513.XA patent/CN114558032A/zh active Pending
- 2013-12-21 ES ES13865661T patent/ES2896354T3/es active Active
- 2013-12-21 CA CA2896053A patent/CA2896053A1/en active Pending
- 2013-12-21 US US14/653,969 patent/US10426799B2/en active Active
-
2014
- 2014-10-16 US US14/515,619 patent/US9993503B2/en active Active
-
2016
- 2016-04-08 HK HK16104031.5A patent/HK1216148A1/zh unknown
- 2016-05-25 HK HK16106000.7A patent/HK1217917A1/zh unknown
-
2017
- 2017-08-15 US US15/677,770 patent/US10894065B2/en active Active
-
2018
- 2018-05-08 US US15/974,597 patent/US20180318353A1/en active Pending
-
2019
- 2019-07-10 JP JP2019128551A patent/JP6875464B2/ja active Active
- 2019-08-01 US US16/528,803 patent/US11400118B2/en active Active
-
2020
- 2020-12-08 US US17/114,685 patent/US20210161964A1/en active Pending
-
2021
- 2021-04-22 JP JP2021072813A patent/JP7432554B2/ja active Active
-
2022
- 2022-05-24 US US17/752,505 patent/US20230028239A1/en active Pending
-
2023
- 2023-12-04 JP JP2023204772A patent/JP2024070856A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7432554B2 (ja) | 多能性幹細胞から血小板を生産するための方法およびその組成物 | |
US20220090008A1 (en) | Colony forming medium and use thereof | |
US20200080059A1 (en) | Generation of hematopoietic progenitor cells from human pluripotent stem cells | |
JPWO2008056779A1 (ja) | 霊長類動物胚性幹細胞の培養及び継代方法、並びにその分化誘導方法 | |
RU2757818C2 (ru) | Способы и композиции для трансплантации стволовых клеток | |
WO2015004609A2 (en) | Adherent cells from placenta and use thereof in treatment of injured tendons | |
US20100197016A1 (en) | Structure enclosing hematopoietic progenitor cells from ES cells and method for preparing blood cells using the same | |
KR20180086301A (ko) | 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성 | |
Deutsch et al. | Mimicking the haematopoietic niche microenvironment provides a novel strategy for expansion of haematopoietic and megakaryocyte‐progenitor cells from cord blood | |
KR101132858B1 (ko) | 내피전구세포의 체외 증폭방법 | |
Lewis | Development of a three-dimensional haematopoietic stem cell-permissive bone marrow niche model using magnetic levitation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161221 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161221 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20161221 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170330 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171004 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171227 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180307 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180615 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180913 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181003 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190710 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190719 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190805 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190904 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6584956 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |